1. Home
  2. ESPR vs FPH Comparison

ESPR vs FPH Comparison

Compare ESPR & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESPR
  • FPH
  • Stock Information
  • Founded
  • ESPR 2008
  • FPH 2009
  • Country
  • ESPR United States
  • FPH United States
  • Employees
  • ESPR N/A
  • FPH N/A
  • Industry
  • ESPR Biotechnology: Pharmaceutical Preparations
  • FPH Real Estate
  • Sector
  • ESPR Health Care
  • FPH Finance
  • Exchange
  • ESPR Nasdaq
  • FPH Nasdaq
  • Market Cap
  • ESPR 410.2M
  • FPH 398.9M
  • IPO Year
  • ESPR 2013
  • FPH 2017
  • Fundamental
  • Price
  • ESPR $1.89
  • FPH $6.15
  • Analyst Decision
  • ESPR Buy
  • FPH
  • Analyst Count
  • ESPR 6
  • FPH 0
  • Target Price
  • ESPR $7.25
  • FPH N/A
  • AVG Volume (30 Days)
  • ESPR 5.1M
  • FPH 611.6K
  • Earning Date
  • ESPR 02-25-2025
  • FPH 01-23-2025
  • Dividend Yield
  • ESPR N/A
  • FPH N/A
  • EPS Growth
  • ESPR N/A
  • FPH N/A
  • EPS
  • ESPR N/A
  • FPH 0.46
  • Revenue
  • ESPR $295,451,000.00
  • FPH $237,926,000.00
  • Revenue This Year
  • ESPR $186.04
  • FPH N/A
  • Revenue Next Year
  • ESPR $11.25
  • FPH N/A
  • P/E Ratio
  • ESPR N/A
  • FPH $13.34
  • Revenue Growth
  • ESPR 187.12
  • FPH 12.37
  • 52 Week Low
  • ESPR $1.58
  • FPH $2.83
  • 52 Week High
  • ESPR $3.94
  • FPH $6.71
  • Technical
  • Relative Strength Index (RSI)
  • ESPR 39.38
  • FPH 73.88
  • Support Level
  • ESPR $1.71
  • FPH $3.96
  • Resistance Level
  • ESPR $2.26
  • FPH $6.71
  • Average True Range (ATR)
  • ESPR 0.14
  • FPH 0.36
  • MACD
  • ESPR -0.01
  • FPH 0.15
  • Stochastic Oscillator
  • ESPR 33.33
  • FPH 80.74

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Commercial. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: